Investor Relations
Q4 Launches Q, the First IRO Agent™

Q4, Inc., the leading provider of IR Ops software, launches Q, the first AI-powered IRO Agent™—reports IR7 Newswire.
Q is changing the paradigm of investor relations by transforming the way investors manage, analyze, and communicate. It is powered by proven AI capabilities. The IRO Agent integrates into the Q4 platform, delivering real-time information, automation, and strategic guidance to investor relations professionals.
Q delivers intelligent data analysis, customized insights, real-time engagement analytics, strategic communications support, and AI-powered analytics. Designed to seamlessly integrate into the Q4 platform, it offers a single, intuitive user interface.
The Agent helps IRO teams save time, gain insights, and increase returns.
News by www.ir7.com
Investor Relations
Global Corrugated Fiberboard Machinery Market—Forecast to 2032

Automation and intelligent integration are improving manufacturing efficiency and meeting the growing demand for sustainable and customizable packaging solutions.
The global corrugated fiberboard machine market is segmented by technology type, machine type, and end user. The market is growing due to e-commerce, rising demand for retail packaging, and eco-friendly packaging solutions.
Leading manufacturers are implementing monitoring, automated diagnostics, and predictive maintenance to optimize productivity. The market continues to invest in lightweight, recyclable material handling equipment.
Integrated intelligent systems such as IoT-enabled monitoring and digital printing are improving productivity and reducing manufacturing costs. Asia Pacific dominates the market with the largest revenue share. North America is the fastest growing region in the market with a projected growth rate of 5.6% between 2025 and 2032.
News from www.ir7.com
Economics
IR in IPOs of biotech companies

IR in IPOs of early-stage biotech companies: from scientific hypothesis to investor trust
IPO for biotech startups is a test of trust formed by IR: trust in science, in technology, in the team, in the company’s ability to build transparent, sustainable communication with the market.
The right IR strategy turns a high-risk placement into a market success. The combination of IPO and IR is critical for biotech. Investor Relations in biotechnology is a tool for shaping the perception of scientific history.
One of the tasks of IR in the framework of IPO is to translate scientific and technical information into the language of value for the investor.
News from www.ir7.com